Every cell in the body normally has its fixed place as part of a tissue structure. Except for a few cell types, such as blood ...

Successful test in breast cancer patients: the active agent digoxin, a cardiac medication, dissolves clusters of circulating breast cancer cells in the blood, thus reducing the risk of metastases ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Reference: Kurzeder C, Nguyen-Sträuli BD, Krol I, et al. Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. Nat Med. 2025. doi: 10.1038 ...

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

9, 2024 — Metastasis is responsible for 90 percent of cancer deaths ... Inhibiting a Key Immune Cell Sep. 27, 2024 — Estrogens are known to drive tumor growth in breast cancer cells that ...

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

A research team at KAIST has identified the core gene expression networks regulated by key proteins that fundamentally drive phenomena such as cancer development, metastasis, tissue differentiation ...

Prostate cancer is one of the most prevalent cancers among men and poses a significant health concern, with its incidence on ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical ...